Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 228

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 228
---
 to following such missed payment (however, for the avoidance of doubt,
any penalty interest that has accrued as the result of any prior payment failure in respect of which Oramed’s Termination Right was not exercised shall be payable together with the Option Fee upon any subsequent exercise of Oramed’s
Termination Right pursuant to ); and (ii) the effectiveness of such penalty interest arising from a payment failure being contingent upon the lapse of Oramed’s Termination Right with respect to and
arising from such payment failure shall not be construed to delay the accrual of interest, which shall commence on the applicable unpaid Option Closing Payment Date.

3

For the avoidance of doubt, if Oramed exercises its Termination Right, then no interest
shall be payable pursuant to this .

(d) .

(i) Oramed, in its capacity as the sole holder of the Tranche A Note, hereby (y) consents to the transactions
contemplated by this Agreement and (z) agrees with Scilex that, notwithstanding anything to the contrary in the Tranche A Note, any other Transaction Document (as defined in the SPA), in the BRE Organizational Documents (as defined in the
Tranche A Note) or the SPV Organizational Documents (as defined in the Tranche A Note):

(A) upon the receipt by Oramed of
(i) both the First Option Closing Payment and the Second Option Closing Payment and (ii) both the First Warrant Payment and the Final Warrant Payment (in each case of clauses (i) and (ii), together with any interest accrued thereon
pursuant to ) (the time all such payments have been received by Oramed, the “”):

(I) the definition of “Maturity Date” (as defined in the Tranche A Note) shall be deemed
automatically amended and restated to mean “March 31, 2026”, without the necessity of any further amendment or action by any Person;

(II) no Make-Whole Amount shall be required to be paid following the Trigger Date in connection with any
repayment (including any Voluntary Prepayment) under the Tranche A Note;

(III) the Subject Warrants, any
shares of Common Stock issuable upon exercise of the Subject Warrants, and any proceeds from the sale of such shares, do not and shall not constitute Collateral under any Transaction Document and shall not be subject to any covenants restricting the
sale or other disposition of such warrants or shares